Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Total Assets
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) holds total assets worth CN¥2.40 Billion CNY (≈ $351.21 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Total Assets Trend (2017–2025)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. Also see market value of Hubei Biocause Heilen Pharmaceutical Co. for the company's overall valuation and market capitalisation.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total assets of CN¥2.40 Billion consist of 74.6% current assets and 25.4% non-current assets. Review Hubei Biocause Heilen Pharmaceutical Co. (301211) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.6% |
| Accounts Receivable | CN¥63.47 Million | 2.6% |
| Inventory | CN¥122.68 Million | 5.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥70.44 Million | 2.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hubei Biocause Heilen Pharmaceutical Co. stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s current assets represent 74.6% of total assets in 2025, an increase from 65.6% in 2017.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2025, up from 9.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 8.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 5.1% of total assets.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Total Assets
Key competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.18 | 13.67 | 7.45 |
| Quick Ratio | 15.97 | 12.69 | 6.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.69 Billion | CN¥1.72 Billion | CN¥572.14 Million |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.13 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | CN¥2.40 Billion |
| Market Capitalization | $723.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below shows the annual total assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.40 Billion ≈ $351.47 Million |
-3.49% |
| 2024-12-31 | CN¥2.49 Billion ≈ $364.17 Million |
-2.27% |
| 2023-12-31 | CN¥2.55 Billion ≈ $372.64 Million |
+1.96% |
| 2022-12-31 | CN¥2.50 Billion ≈ $365.50 Million |
+7.18% |
| 2021-12-31 | CN¥2.33 Billion ≈ $341.00 Million |
+190.11% |
| 2020-12-31 | CN¥803.25 Million ≈ $117.54 Million |
+7.74% |
| 2019-12-31 | CN¥745.56 Million ≈ $109.10 Million |
+16.45% |
| 2018-12-31 | CN¥640.24 Million ≈ $93.69 Million |
+19.69% |
| 2017-12-31 | CN¥534.90 Million ≈ $78.27 Million |
-- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more